Akeso, Inc. (HK:9926) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akeso, Inc. has announced significant progress in the treatment of PD-L1 positive advanced NSCLC with its drug ivonescimab, showing a marked improvement over pembrolizumab in a recent Phase III clinical trial. The drug not only achieved a median progression-free survival (PFS) of 11.14 months versus 5.82 for the control but also demonstrated a better overall response rate and disease control rate. These promising results have led to the acceptance of a supplemental New Drug Application by China’s NMPA and plans for further international Phase III trials.
For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money